Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Centre for Biomedical Research Network for Hepatic and Digestive Diseases, Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, C/ Villarroel 170, 08036 Barcelona, Spain.
- Alejandro Forner &
- Jordi Bruix
Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte Marguerite, 13009 Marseille, France.
- Marine Gilabert &
- Jean-Luc Raoul
A.F., J.B. and J.-L.R. contributed to all stages of the preparation of the manuscript for submission. M.G. made substantial contributions researching data for article, discussion of content, and review/editing of the manuscript before submission.
Competing interests statement
A.F. has acted as a consultant for Bayer HealthCare. J.B. has acted as a consultant or in an advisory role for ArQule, Bayer, Biocompatibles, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Kowa, Lilly, Novartis, Roche, and Terumo. J.-L.R. has acted as a consultant or in an advisory role for Arqule, Bayer HealthCare, Biocompatibles, Bristol-Myers Squibb, and Merck Serono. M.G. declares no competing interests.
Alejandro Forner, MD, PhD, achieved his medical degree at the University Miguel Hernández, Alicante, Spain, in 1999, obtaining the Extraordinary Licensure Award for the best medical school academic expedient. He obtained the Board certification in Gastroenterology and Hepatology in the Liver and Gastroenterology Unit, Hospital Clinic, Barcelona (2001–2005) and since 2005, has worked at the Barcelona Clinic Liver Cancer (BCLC) group directed by Prof. Bruix. His clinical activity is based on the care of cirrhotic patients with hepatocellular carcinoma (HCC) and his investigational fields are the early diagnosis (doctoral thesis) and the treatment of advanced-stage HCC. He was co-investigator and co-author of the SHARP study. In addition, he is Associate Editor of Liver International, and has acted as reviewer for the most-cited peer-reviewed journals in hepatology (Hepatology, Gut, Journal of Hepatology and Liver Transplantation) and oncology (Lancet Oncology). Finally, he has authored several original papers, editorials and reviews on HCC and he is the first author of the Spanish Guidelines for HCC management.
Marine Gilabert, MD, PhD, is a medical oncologist and Assistant Professor at the Gastrointestinal Oncology Team in the Comprehensive Cancer Centre, Paoli-Calmettes Institute, Marseille, France. She graduated in Oncology in 2011 from Mediterranee University, Aix-Marseille, France, following medical studies at Aix-Marseille University, France. She is a member of the Clinical Research Team, Centre de Recherche en Cancerologie de Marseille, INSERM UMR 1068, Paoli-Calmettes Institute, Aix-Marseille University, France, where she completed her PhD in 2014. Dr Gilabert is currently Principal Investigator in a biological study of human pancreatic cancer and a Clinical Investigator in several phase I, II, and III oncological studies, specially gastrointestinal studies, including first human dose trials.
Jordi Bruix, MD, PhD, is Director of the BCLC group within the Liver Unit at the Hospital Clínic of Barcelona, University of Barcelona, Catalonia, Spain. He has been Principal Investigator of studies and clinical trials that have changed practice in the field of HCC, including the development of diagnostic criteria and prognostic models, and establishing chemoembolization and sorafenib as standard therapies. He has developed and sequentially updated the BCLC staging and treatment strategy that has been endorsed by several international scientific associations to guide the management of patients with HCC. Dr Bruix is a member of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). He founded the International Liver Cancer Association (ILCA) and was nominated President from 2006 to 2009. He has been Associate Editor of Journal of Hepatology, Liver Transplantation, and Hepatology, and is currently Associate Editor of Seminars in Liver Disease. Dr Bruix has authored more than 200 peer reviewed manuscripts and the Evidence-based Practice Guidelines for Hepatocellular Carcinoma at EASL, AASLD and World Gastroenterology Organization (WGO), as well as consensus statements to define endpoints in clinical trials that have paved the design and analysis of such investigations.
Jean-Luc Raoul, MD, PhD, is hepatogastroenterologist and medical oncologist. He is currently Head of the Gastrointestinal Oncology Team at the Comprehensive Cancer Centre, Paoli-Calmettes Institute. He has held the position of Professor of Medical Oncology at Rennes University since 2000, and in 2005 he was appointed Visiting Professor at the University of Perth-Fremantle, Western Australia. Jean-Luc Raoul has clinical and research interests in gastrointestinal cancers mainly oesophageal and pancreatic cancers and HCC, in particular the application of targeted internal radiation therapy and targeted therapies in HCC. He is a member of several societies including the American Society of Clinical Oncology (ASCO), the ILCA, the EASL, the ESMO (European Society of Medical Oncology. He has authored or co-authored more than 200 papers, particularly in the field of HCC.